tbuckley/cabot-search huggingface dataset:
Abstract P293: Perivascular Adipose Tissue of the Descending Aorta is Associated with SLE and Vascular Calcification
Authors: Kelly J Shields, Emma Barinas-Mitchell, Ping Tepper, Matthew R Gingo, Amy H Kao, Susan Manzi, Kim Sutton-Tyrrell
Journal: Circulation (2012)

Introduction: Women with systemic lupus erythematosus (SLE) have an increased risk of cardiovascular disease (CVD). Traditional CVD and SLE related risk factors have been implicated, but do not fully account for this increased risk. Adipose produces pro-atherogenic components and visceral adipose is most strongly associated with vascular dysfunction and metabolic disorder. The proximity of perivascular adipose tissue (PVAT) to blood vessels may exacerbate vascular dysfunction and progression of CVD. Hypothesis: We hypothesized that SLE participants have increased PVAT surrounding the descending thoracic aorta with increased coronary artery calcification (CAC) and aortic calcification (AC) compared to healthy controls. PVAT is hypothesized to be positively associated with increased CAC and AC. Methods: Women participating in the: “Heart Effects on Atherosclerosis and Risk of Thrombosis in SLE” (HEARTS) study were clinically CVD-free, diagnosed with SLE for 2 years and age and race matched to healthy women, excluding those with diabetes (SLE, n=153; Control, n=158). The EBT scans were performed using an Imatron C-150 scanner. CAC/AC were quantified using Agatston scores and the PVAT was quantified using standard attenuations values for adipose tissue (−190 to −30 HU) on commercially available software. The total PVAT volume (tPVAT) was calculated by summing the areas and multiplying by the length of the participant’s aorta. Results and Conclusions: The SLE group had a greater tPVAT than the control group (p=0.0071) despite no differences in age, BMI, metabolic syndrome (MS), or waist or hip circumference. The SLE group was more likely to be hypertensive (p&lt;0.0001) and had a larger waist to hip ratio (p=0.001 ) reflecting vascular dysfunction and a different adipose distribution. Total PVAT was associated with SLE (OR: 1.02, p=0.020) and the association remained significant after adjusting for CVD risk factors including BMI and MS (OR: 1.03, p=0.028). Based on linear regression analysis, the tPVAT in both SLE and controls was influenced by postmenopausal status, CRP, BMI, and MS, while history of smoking also influenced the control tPVAT. Unadjusted AC was associated with SLE by a factor of 2.3 (p=0.01), while there was no statistical difference between SLE and control for CAC. In logistic regression analysis, tPVAT was associated with AC (1.07,p&lt;0.0001), which remained significant after adjusting for CVD and inflammatory factors including BMI and MS. The CAC (1.05,p&lt;0.0001) association was attenuated with BMI and MS. In conclusion, tPVAT is greater in clinically CVD-free SLE versus control participants and is associated with AC independent of overall adiposity.
Lack of Influence of T-Cell Marker and Importance of Mediastinal Mass on the Prognosis of Acute Lymphocytic Leukemias of Childhood<xref ref-type="fn" rid="fn2">2</xref><xref ref-type="fn" rid="fn3">3</xref>
Authors: H W Hann, E D Lustbader, A E Evans, S R Toledano, P D Lillie, L B Jasko
Journal: JNCI Journal of the National Cancer Institute (1981)

One hundred consecutive new cases of acute lymphocytic leukemia (ALL) were studied in patients that were 4 months to 16 years of age when admitted to The Children's Hospital of Philadelphia. Various prognostic factors were examined and related to the duration of the first remission. These factors included lymphoblast surface markers, age at diagnosis, sex, race, initial white blood counts (WBC), presence of mediastinal mass, degree of hepatosplenomegaly, and lymph node size. Classification by lymphoblast surface markers showed 22 T-cell, 71 null cell, and 3 B-cell leukemias; 3 cases were unclassifiable and 1 had both T- and B-cell markers. Statistical analysis indicated that stratification by presence or absence of mediastinal mass was necessary. Most patients with mediastinal masses, 5 of thymus and 4 of the non-thymus type, fared poorly with a median duration of continuous complete remission of less than 12 months as compared with greater than 48 months for those without such masses. The most satisfactory model to estimate remission duration in children without mediastinal masses was dependent upon initial WBC, sex, race, and surface markers. Low WBC, white race, female sex, and T-cell markers in patients without mediastinal masses were associated with a favorable prognosis. The findings suggest that patients with mediastinal masses need special therapy and that T-cell ALL without a mediastinal masses need special therapy and that T-cell ALL without a mediastinal mass does not carry a poorer prognosis than does null cell ALL.
OC-107 Gas chromatography sensor platform for diagnosing inflammatory bowel disease and irritable bowel syndrome using faecal samples: Abstract OC-107 Table 1
Authors: R Aggio, P White, B de Lacy Costello, N Ratcliffe, C Probert
Journal: Gut (2015)

<h3>Introduction</h3> Inflammatory bowel disease (IBD) is a chronic gastrointestinal disease caused by an aberrant immune response in the gut. Irritable bowel syndrome (IBS) is a common disease that may be confused with IBD. Faecal calprotectin concentration is the current recommended biomarker to rule out IBD, but there are no tests to positively diagnose IBS. Consequently, expensive and invasive methods involving colonoscopy and biopsy are still used by many clinicians to rule out other pathologies. Here, we propose a platform for accurately diagnose IBD and IBS based on faecal samples. <h3>Method</h3> The platform is composed of a gas chromatography coupled to a metal oxide gas sensor (OdoReader) and a computer algorithm. The OdoReader separates the volatile organic compounds (VOCs) present in biological samples, while the computer algorithm identifies resistance patterns associated with specific medical conditions and builds mathematical models to classify unknown samples. This platform was applied to faecal samples collected from 98 patients attending the gastroenterology clinic: 45 patients with active IBD; 24 patients with diarrhoea-predominant IBS; and 29 healthy donors (Control). The following comparisons were performed: IBD vs. IBS; IBD vs. Control; IBS vs. Control; IBD vs. non-IBD (IBS + Control); IBS vs. non-IBS (IBD + Control); Control vs. non-Control (IBD + IBS). The mathematical models developed were validated through rigorous validation schemes namely 10-Fold Cross Validation, Double Cross Validation and their Monte Carlo variations. <h3>Results</h3> <h3>Conclusion</h3> This is the first description of an investigation for the positive diagnosis of IBS. The platform presented here classified samples with accuracies from 85% to 94% using rigorous validation schemes. These schemes provide an estimate of out-of-sample predictive accuracy for similar populations. Therefore, the results reported here indicate a successful differentiation of biological samples from patients with IBD, IBS and healthy donors. These results also indicate a better performance than calprotectin alone for diagnosing IBD, which has been reported as 85% before the application of validation schemes. This platform could be used at point of care for non-invasive diagnosis of IBS and IBD. <h3>Disclosure of interest</h3> None Declared.
MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA
Authors: Xiaoli Liu, Achuthamangalam B. Madhankumar, Patti A. Miller, Kari A. Duck, Susan Hafenstein, Elias Rizk, Becky Slagle-Webb, Jonas M. Sheehan, James R. Connor, Qing X. Yang
Journal: Neuro-Oncology (2015)

Detection of glioma with MRI contrast agent is limited to cases in which the blood-brain barrier (BBB) is compromised as contrast agents cannot cross the BBB. Thus, an early-stage infiltrating tumor is not detectable. Interleukin-13 receptor alpha 2 (IL-13Rα2), which has been shown to be overexpressed in glioma, can be used as a target moiety. We hypothesized that liposomes conjugated with IL-13 and encapsulating MRI contrast agent are capable of passing through an intact BBB and producing MRI contrast with greater sensitivity.The targeted MRI contrast agent was created by encapsulating Magnevist (Gd-DTPA) into liposomes conjugated with IL-13 and characterized by particle size distribution, cytotoxicity, and MRI relaxivity. MR image intensity was evaluated in the brain in normal mice post injection of Gd-DTPA and IL-13-liposome-Gd-DTPA one day apart. The specificity for glioma detection by IL-13-liposome-Gd-DTPA was demonstrated in an intracranial glioma mouse model and validated histologically.The average size of IL-13-liposome-Gd-DTPA was 137 ± 43 nm with relaxivity of 4.0 ± 0.4 L/mmole-s at 7 Tesla. No significant cytotoxicity was observed with MTS assay and serum chemistry in mice. The MRI signal intensity was enhanced up to 15% post injection of IL-13-liposome-Gd-DTPA in normal brain tissue following a similar time course as that for the pituitary gland outside of the BBB. MRI enhanced by IL-13-liposome-Gd-DTPA detected small tumor masses in addition to those seen with Magnevist-enhanced MRI.IL-13-liposome-Gd-DTPA is able to pass through the uncompromised BBB and detect an early stage glioma that cannot be seen with conventional contrast-enhanced MRI.
Preferences and motivations with and without inferences
Authors: Piotr Winkielman, Michael Inzlicht, Eddie Harmon-Jones
Journal: Behavioral and Brain Sciences (2015)

Abstract Pessoa (2013) makes an impressive case that emotion, motivation, and cognition are neurally intertwined. Our commentary broadens the discussion to the functional, “mind” level. We argue that philosophical and computational considerations justify some modern “separatist” views. We highlight several psychological phenomena that illustrate independence, including affective and motivational reactions to rudimentary inputs, and the guiding role of such reactions in cognition.
Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy.
Authors: M F Schray, A Martinez, A E Howes, K C Podratz, S C Ballon, G D Malkasian, B I Sikic
Journal: Journal of Clinical Oncology (1988)

Between 1979 and 1984, 53 patients received whole abdominal irradiation in a curative salvage effort for residual (32 patients) or recurrent (21 patients) epithelial ovarian cancer after combination chemotherapy (cisplatin-based in 48 patients). Residual cancer less than or equal to 2 cm in diameter was confirmed at operation in all patients before irradiation consisting of 2,550 to 3,000 rad to the whole abdomen with partial liver/kidney shielding and boosting of the dose to the diaphragmatic/paraaortic nodal regions and pelvis to approximately 4,000 and 5,000 rad, respectively. Twelve patients (23%) did not complete therapy as a result of hematologic intolerance. Actuarial overall and disease-free survival at 3 years are 35% and 30%, respectively, with follow-up for disease-free patients ranging from 30 to 79 months (median, 43 months). Twenty-seven of 36 relapses (75%) occurred within the irradiated abdomen alone. At 3 years, 70% of patients with well- or moderately-differentiated tumors were disease-free v 10% of those with poorly differentiated tumors (P less than .001). Among prognostic factors evaluated, including grade, initial residual disease before chemotherapy, residual disease at time of irradiation, age, chemotherapy response v progression, and completion of irradiation, only grade and initial residual disease before chemotherapy were statistically significant in multivariate analysis (both P less than .01). Patients with the combination of high-grade tumor, initial residual disease greater than 2 cm before chemotherapy, and macroscopic disease after "second-look" laparotomy do not benefit from irradiation. Eleven patients (21%) developed an apparent treatment-related bowel obstruction after completion of irradiation. Selected subsets of patients do well; however, the role of irradiation in this setting can be confirmed only with randomized clinical study.
Oncogenicity of &lt;italic&gt;Herpesvirus saimiri&lt;/italic&gt; Marmoset Monkeys&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Lauren G. Wolfe, Lawrence A. Falk, Friedrich Deinhardt
Journal: JNCI Journal of the National Cancer Institute (1971)

Herpesvirus saimiri (HVS) consistently induced lymphomas or lymphocytic leukemias in marmosets, Saguinus oedipus, S. nigricollis, and S. fuscicollis, but induced no disease in galagos, Galago crassicaudatus. Lymphoreticular proliferation was present at intramuscular inoculation sites and in nearly all lymphoid tissues as early as 10 days after inoculation. The disease was always fatal, but the course, never longer than 35 days in S. oedipus, was prolonged up to 116 days in S. fuscicollis. Inclusion bodies, viral particles, or virus-associated antigens were not detected in fresh neoplastic tissues or in circulating neoplastic cells, but the HVS genome was demonstrated in these tissues by consistent recovery of HVS after they were cultured in vitro. Virus was recoverable from the circulating leukocytes 2–6 weeks after inoculation, which was the interval when fluorescing and neutralizing antibodies were first detected in the serum. Horizontal transmission to contact-exposed cagemates was not observe.
Parallel Phase I Studies of Two Schedules of Bkm120 Plus Carboplatin and Paclitaxel for Patients with Advanced Solid Tumors
Authors: A. Snyder Charen, D. Hyman, N. Katabi, M. Voss, M. Gounder, K. Monson, M. Stasi, J. Winkelman, J. Gerecitano, R. Carvajal, M. Fury
Journal: Annals of Oncology (2014)
Differences in performance status assessments between palliative care specialists, nurses, and oncologists.
Authors: YuJung Kim, Yi Zhang, Ji Chan Park, David Hui, Gary B. Chisholm, Janet L. Williams, Eduardo Bruera
Journal: Journal of Clinical Oncology (2014)

19 Background: The Eastern Cooperative Oncology Group (ECOG) performance status (PS) is one of the most commonly used assessment tools among oncologists and palliative care specialists caring advanced cancer patients. However, the inter-observer difference between the oncologist and palliative care specialist has never been reported. Methods: We retrospectively reviewed the medical records of all patients who were first referred to an outpatient palliative care clinic in 2013 and identified 278 eligible patients. The ECOG PS assessments by palliative care specialists, nurses, and oncologists, and the symptom burden measured by Edmonton Symptom Assessment Scale (ESAS) were analyzed. Results: According to the pairwise comparisons using Sign tests, palliative care specialists rated the ECOG PS grade significantly higher than oncologists (median 0.5 grade, P&lt;0.0001) and nurses also rated significantly higher (median 1.0 grade, P&lt;0.0001). The assessments of palliative care specialists and nurses were not significantly different (P=0.10). Weighted kappa values for inter-observer agreement were 0.26 between palliative care specialists and oncologists, and 0.61 between palliative care specialists and nurses. Palliative care specialists’ assessments showed a moderate correlation with fatigue, dyspnea, anorexia, feeling of well-being, and symptom distress score measured by ESAS. The ECOG PS assessments by all three groups were significantly associated with survival (P&lt;0.001), but the assessments by oncologists could not distinguish survival of patients with PS 2 from 3. Independent predictors of discordance in PS assessments between palliative care specialists and oncologists were the presence of an effective treatment option (odds ratio [OR] 2.39, 95% confidence interval [CI] 1.09-5.23) and poor feeling of well-being (≥4) by ESAS (OR 2.38, 95% CI 1.34-4.21). Conclusions: ECOG PS assessments by the palliative care specialists and nurses were significantly different from the oncologists. Systematic efforts to increase regular interdisciplinary meetings and communications might be crucial to bridge the gap and establish a best care plan for each advanced cancer patients.
Spontaneous Prostate Adenocarcinomas in Aged Germfree Wistar Rats2
Authors: Morris Pollard
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Spontaneous Prostate Adenocarcinomas in Aged Germfree Wistar Rats Get access Morris Pollard Morris Pollard Lobund Laboratory, University of Notre Dame, Notre Dame, Ind. 46556 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 4, October 1973, Pages 1235–1241, https://doi.org/10.1093/jnci/51.4.1235 Published: 01 October 1973 Article history Received: 02 April 1973 Accepted: 19 June 1973 Published: 01 October 1973
The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis
Authors: Evelina Ferrantelli, Georgios Liappas, Marc Vila Cuenca, Eelco D. Keuning, Thomas L. Foster, Marc G. Vervloet, Manuel Lopéz-Cabrera, Robert H.J. Beelen
Journal: Kidney International (2016)
Induction of Differentiation of Human Promyelocytic Leukemia Cells (HL-60) by Nucleosides and Methotrexate
Authors: A J Bodner, R C Ting, R C Gallo
Journal: JNCI Journal of the National Cancer Institute (1981)

Various purine and pyrimidine analogs and methotrexate were tested to determine whether they induce morphologic and functional myeloid differentiation in HL-60, a human promyelocytic leukemia cell line. Functional maturity was assessed by nitro blue tetrazolium reduction assays. 3-Deazauridine caused nearly all of the cells to differentiate during 6 days of treatment. Pyrazofurin, virazole, puromycin aminonucleoside, and the tricyclic nucleoside 3-amino-1,5-dihydro-5-methyl-1-β-d-ribofuranosyl-1,4,5,6,8-pentaazaacenaphthylene induced maturation in 44–64% of the cells, whereas 5-azacytidine, 5-bromo-2′-deoxyuridine, 5-iodo-2′-deoxyuridine, thymidine, and the antimetabolite methotrexate induced maturation in 28–36% of the cells. In terms of effective concentration, the most potent inducer was methotrexate (10−8M). The predominant cell types after treatment with all of these compounds were the metamyelocyte and banded neutrophilic granulocyte.
포스터 전시 : 간세포암종에서 β-Catenin과 E-cadherin의 돌연변이와 단백 발현
Authors: 강유나, 오훈규, 권선영, 박경식, 조광범, 황재석, 강구정
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 간세포암종은 전세계에 널리 퍼져있는 가장 무서운 암종 중에 하나이다. 그러나 종양의 형성과 진행 과정에 대한 기전은 아직 확실히 알려져 있지 않다. 최근에는 간세포암종의 약 20%에서 β-catenin 유전자의 돌연변이가 관찰된 바 있다. 본 연구에서 간세포암종과 간세포암종 세포주에서 β-catenin과 E-cadherin 유전자의 돌연변이와 단백 발현의 변화를 살펴보고자 하였다. 대상과 방법: 19 예의 간세포암종과 10 가지의 간세포암종 세포주(SNU182, SNU354, SNU368, SNU387, SNU398, SNU423, SNU449, SNU475, Hep3B, HepG2)에서 DNA를 추출한 후 중합효소 연쇄반응을 거친 후 염기서열 결정법을 통해 돌연변이를 관찰하였고 Western blotting, RT-PCR, methylation specific PCR, 그리고 면역조직화학 염색을 실시하였다. 결과: 간세포암종 3 예(15.7%)와 SNU398 세포주에서 β-catenin exon 3 유전자 돌연변이를 관찰하였고, Hep3B 세포주에서 E-cadherin exon 9 유전자 돌연변이를 발견하였다. Methylation specific PCR을 통해 4 예(21.1%)의 간세포암종에서 E-cadherin CpG 촉진자 부위에서 메틸화가 일어나 있음을 관찰하였다. RT-PCR과 Western blot 분석 결과 β-catenin 단백 발현이 간세포암종 87.5%의 종양 조직에서 증가하였고, E-cadherin mRNA와 단백 발현은 간세포암종 71.4%와 85.7%에서 각각 감소하였다. 면역조직화학염색에서도 β-catenin 단백 발현은 간세포암종 63.2%에서 종양 세포의 세포막에서 발현이 증가하였고, E-cadherin 단백 발현은 간세포암종 52.6%에서 감소하였다. 결론: β-Catenin 유전자 돌연변이는 β-catenin mRNA와 단백 발현의 증가를 유발하고, 또 E-cadherin 메틸화는 E-cadherin mRNA와 단백 발현의 감소를 유발하여 β-catenin 단백 발현의 증가와 연관성을 가진다. 따라서 β-catenin 유전자 돌연변이와 E-cadherin 메틸화는 β-catenin 단백 발현의 증가를 동반하여 간세포암종의 형성에 관여한다고 볼 수 있다.
Breast cancer (BC): May intra-arterial (IA) chemotherapy (CT) play a role in the treatment of locally advanced disease or liver metastases? Report of our experience
Authors: C. Milandri, F. Calzolari, A. Passardi, E. Giampalma, C. Tison, L. Cecconetto, S. Calpona, L. Ridolfi
Journal: Journal of Clinical Oncology (2006)

10726 Background: IA infusion of CT increases drug concentrations within a tumor. We investigated if it is effective in BC patients (pts) with locally advanced disease or liver metastases. Methods: Twenty-five pts were treated with IA CT using angiographic technique in the Department of Medical Oncology, Morgagni-Pierantoni Hospital in Forlì. Pts received a short IA infusion through the proper hepatic artery (liver metastases) or the internal mammary artery (locally advanced disease). Drugs were: Epirubicin (EPI) 30 mg/m 2 , Mitomycin-c (MMC) 7 mg/m 2 and 5-fluoruracil (5FU) 1000 mg on day 1 every 21 days. EPI was not administered in anthracycline pretreated pts. Results: Median age was 54.3 years (31–75 years) and ECOG Performance Status (PS) was ≤2. Nine pts had liver metastases and 16 had locally advanced disease. Twenty-three (96%) of the 25 pts had received adjuvant treatment (21 CT, 7 endocrine therapy), 20 (80%) had had at least one treatment for metastatic disease (20 CT, 11 endocrine therapy, 8 radiotherapy), and 11 pts (40%) had received concomitant therapy (3 CT and 8 endocrine). Fifteen pts were anthracycline-naïve. A total of 88 angiographic sessions were carried out, with a median number of 3.5 cycles per patient (1–8 cycles). One transitory ischaemic attack occurred during angiographic procedure . No other serious complications were observed. The only cases of toxicity higher than grade 2 were one grade III neutropenia and one grade IV thrombocytopenia. A dose reduction was necessary in 4 pts (2 due to PS, 1 to toxicity and 1 to pre-treatment) and treatment was interrupted in 4 pts (2 due to PS, 1 to early progression and 1 to technical problems). Among the 19 pts assessable for response, 13 (68%) had a partial response, 2 (11%) showed stable disease and 4 (21%) progressed. Median time to progression and median overall survival will be given. Conclusions: Our results suggest that IA CT may play a role in the treatment of advanced pre-treated BC pts. No significant financial relationships to disclose.
Effects of cyclosporine and its metabolites in the isolated perfused rat kidney.
Authors: K A Roby, L M Shaw
Journal: Journal of the American Society of Nephrology (1993)

The isolated perfused rat kidney (IPK) was used to study the acute effects of cyclosporin A (CsA) and its metabolites (M1, M17, M18, M21 and M-COOH). GFR, renal vascular resistance, and sodium, potassium and water reabsorption were measured before and after the addition of CsA/metabolites/vehicles. There was no difference in CsA effect (mild decrease in GFR and increase in renal vascular resistance with the inclusion of plasma (10 mL) or whole blood (20 mL) in the albumin perfusate (120 mL). Intralipid was used as the vehicle for CsA and the metabolites because methanol, ethanol, and Cremophor had significant effects on GFR. Intralipid enhanced the effect of CsA 25-fold, giving CsA dose responses comparable to those of human kidneys. This enhanced effect with intralipid was due to vasoconstriction, not vascular obstruction, and was apparently specific to CsA (no enhancement of norepinephrine with Intralipid). The primary metabolites (M1, M17, and M21) caused decreases in GFR comparable to or slightly less than those caused by CsA. The secondary metabolites (M18 and M-COOH) caused more modest declines in GFR. Cyclosporine metabolite levels in patient blood often greatly exceed levels of the parent drug; these studies suggest that the metabolites may contribute significantly to CsA nephrotoxicity in patients.